Published in Inorg Chem on April 25, 2017
A short history of SHELX. Acta Crystallogr A (2007) 7339.18
UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem (2004) 112.47
AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem (2009) 23.19
A consistent and accurate ab initio parametrization of density functional dispersion correction (DFT-D) for the 94 elements H-Pu. J Chem Phys (2010) 11.76
Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science (1996) 9.48
Balanced basis sets of split valence, triple zeta valence and quadruple zeta valence quality for H to Rn: Design and assessment of accuracy. Phys Chem Chem Phys (2005) 7.19
Platinum compounds: a new class of potent antitumour agents. Nature (1969) 5.92
Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev (2006) 5.08
Quantitative visualization of DNA G-quadruplex structures in human cells. Nat Chem (2013) 4.61
Effect of the damping function in dispersion corrected density functional theory. J Comput Chem (2011) 4.22
A tetrameric DNA structure with protonated cytosine.cytosine base pairs. Nature (1993) 4.03
Climbing the density functional ladder: nonempirical meta-generalized gradient approximation designed for molecules and solids. Phys Rev Lett (2003) 3.63
MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer (2013) 3.60
Targeting G-quadruplexes in gene promoters: a novel anticancer strategy? Nat Rev Drug Discov (2011) 3.54
The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans (2010) 2.48
Human telomeric DNA: G-quadruplex, i-motif and Watson-Crick double helix. Nucleic Acids Res (2002) 2.35
A hitchhiker's guide to G-quadruplex ligands. Org Biomol Chem (2007) 2.27
Organometallic anticancer compounds. J Med Chem (2010) 2.19
Accurate Coulomb-fitting basis sets for H to Rn. Phys Chem Chem Phys (2006) 1.72
Role of glutathione in cancer progression and chemoresistance. Oxid Med Cell Longev (2013) 1.68
Molecular characterization of the hdm2-p53 interaction. J Mol Biol (1997) 1.64
The application of DNA and RNA G-quadruplexes to therapeutic medicines. Chem Soc Rev (2011) 1.54
Ruthenium half-sandwich complexes bound to protein kinase Pim-1. Angew Chem Int Ed Engl (2006) 1.54
A proton-fuelled DNA nanomachine. Angew Chem Int Ed Engl (2003) 1.42
Fluorescence-based melting assays for studying quadruplex ligands. Methods (2007) 1.38
Screening the p53 status of human cell lines using a yeast functional assay. Mol Carcinog (1997) 1.38
APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. Lung Cancer (2009) 1.37
Arene ruthenium complexes as anticancer agents. Dalton Trans (2009) 1.29
Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy. Met Based Drugs (2010) 1.25
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment. J Med Chem (2014) 1.21
Structure-Based Design of Inhibitors of Protein-Protein Interactions: Mimicking Peptide Binding Epitopes. Angew Chem Int Ed Engl (2015) 1.17
Bismuth in medicine. Met Ions Biol Syst (2004) 1.16
Gold compounds as therapeutic agents for human diseases. Metallomics (2011) 1.12
Structural and solution chemistry, antiproliferative effects, and DNA and protein binding properties of a series of dinuclear gold(III) compounds with bipyridyl ligands. J Med Chem (2006) 1.12
Advances in copper complexes as anticancer agents. Chem Rev (2013) 1.12
Structurally sophisticated octahedral metal complexes as highly selective protein kinase inhibitors. J Am Chem Soc (2011) 1.11
Cisplatin resistance associated with PARP hyperactivation. Cancer Res (2013) 1.11
A metal-based inhibitor of tumor necrosis factor-α. Angew Chem Int Ed Engl (2012) 1.06
Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs. Chem Soc Rev (2013) 1.04
Chemical biology of anticancer gold(iii) and gold(i) complexes. Chem Soc Rev (2015) 1.04
Ferrocene-mediated proton-coupled electron transfer in a series of ferrocifen-type breast-cancer drug candidates. Angew Chem Int Ed Engl (2005) 1.03
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. Chem Rev (2016) 1.02
The transcriptional complex between the BCL2 i-motif and hnRNP LL is a molecular switch for control of gene expression that can be modulated by small molecules. J Am Chem Soc (2014) 1.02
Benzimidazol-2-ylidene gold(I) complexes are thioredoxin reductase inhibitors with multiple antitumor properties. J Med Chem (2010) 1.00
A golden future in medicinal inorganic chemistry: the promise of anticancer gold organometallic compounds. Dalton Trans (2014) 0.99
Metallodrugs in medicinal inorganic chemistry. Chem Rev (2014) 0.97
Metal-based inhibition of poly(ADP-ribose) polymerase--the guardian angel of DNA. J Med Chem (2011) 0.97
N-Heterocyclic carbene metal complexes in medicinal chemistry. Dalton Trans (2012) 0.96
i-Motif DNA: structure, stability and targeting with ligands. Bioorg Med Chem (2014) 0.96
Platinum-based drugs: past, present and future. Cancer Chemother Pharmacol (2016) 0.95
I-motif formation in gene promoters: unusually stable formation in sequences complementary to known G-quadruplexes. Chem Commun (Camb) (2012) 0.93
Insights into the biomedical effects of carboxylated single-wall carbon nanotubes on telomerase and telomeres. Nat Commun (2012) 0.91
Comparative in vitro evaluation of N-heterocyclic carbene gold(I) complexes of the benzimidazolylidene type. J Med Chem (2011) 0.91
Multinuclear cytotoxic metallodrugs: physicochemical characterization and biological properties of novel heteronuclear gold-titanium complexes. Inorg Chem (2011) 0.87
Caffeine-based gold(I) N-heterocyclic carbenes as possible anticancer agents: synthesis and biological properties. Inorg Chem (2014) 0.85
State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors. Chem Soc Rev (2015) 0.84
Advances in metal-carbene complexes as potent anti-cancer agents. Metallomics (2011) 0.82
Interactions of selected gold(III) complexes with calf thymus DNA. Biochem Biophys Res Commun (2001) 0.82
Cyclometalated gold(III) complexes with N-heterocyclic carbene ligands as topoisomerase I poisons. Chem Commun (Camb) (2010) 0.81
Gold(III) complexes containing N-heterocyclic carbene ligands: thiol "switch-on" fluorescent probes and anti-cancer agents. Angew Chem Int Ed Engl (2013) 0.81
Cellular transport mechanisms of cytotoxic metallodrugs: an overview beyond cisplatin. Molecules (2014) 0.81
Identification of a new p53/MDM2 inhibitor motif inspired by studies of chlorofusin. Bioorg Med Chem Lett (2015) 0.81
Fragment-based screening of the donor substrate specificity of human blood group B galactosyltransferase using saturation transfer difference NMR. J Biol Chem (2006) 0.81
Synthesis and luminescence modulation of pyrazine-based gold(iii) pincer complexes. Chem Commun (Camb) (2015) 0.80
Inhibition of the cathepsin cysteine proteases B and K by square-planar cycloaurated gold(III) compounds and investigation of their anti-cancer activity. J Inorg Biochem (2011) 0.79
Assessing the differential affinity of small molecules for noncanonical DNA structures. Chembiochem (2012) 0.79
Luminescent cyclometalated N-heterocyclic carbene-containing organogold(III) complexes: synthesis, characterization, electrochemistry, and photophysical studies. J Am Chem Soc (2009) 0.78
Exploring the potential of gold(III) cyclometallated compounds as cytotoxic agents: variations on the C^N theme. Dalton Trans (2015) 0.78
Strong inhibition of thioredoxin reductase by highly cytotoxic gold(I) complexes. DNA binding studies. J Inorg Biochem (2013) 0.77
A gold coordination compound as a chemical probe to unravel aquaporin-7 function. Chembiochem (2014) 0.77
Unique Use of Alkylation for Chemo-Redox Activity by a Pt(IV) Prodrug. Chemistry (2016) 0.77
Cyclometalated Iminophosphorane Gold(III) and Platinum(II) Complexes. A Highly Permeable Cationic Platinum(II) Compound with Promising Anticancer Properties. J Med Chem (2015) 0.76
Mitoxantrone and Analogues Bind and Stabilize i-Motif Forming DNA Sequences. Sci Rep (2016) 0.76
A dual cytotoxic and anti-angiogenic water-soluble gold(III) complex induces endoplasmic reticulum damage in HeLa cells. Chem Commun (Camb) (2012) 0.76
Determinants for Tight and Selective Binding of a Medicinal Dicarbene Gold(I) Complex to a Telomeric DNA G-Quadruplex: a Joint ESI MS and XRD Investigation. Angew Chem Int Ed Engl (2016) 0.76
Unveiling the "Three-Finger Pharmacophore" Required for p53-MDM2 Inhibition by Saturation-Transfer Difference (STD) NMR Initial Growth-Rates Approach. Chemistry (2016) 0.76
Interactions of selected gold(III) complexes with DNA G quadruplexes. Dalton Trans (2015) 0.76
Development of trackable metal-based drugs: new generation of therapeutic agents. Dalton Trans (2016) 0.76
Luminescent Gold(III) Thiolates: Supramolecular Interactions Trigger and Control Switchable Photoemissions from Bimolecular Excited States. Chemistry (2016) 0.76
Cyclometalated Gold(III) Complexes Containing N-Heterocyclic Carbene Ligands Engage Multiple Anti-Cancer Molecular Targets. Angew Chem Int Ed Engl (2017) 0.76
Reversible DNA i-motif to hairpin switching induced by copper(II) cations. Chem Commun (Camb) (2015) 0.76
Stereo- and Regioselective Alkyne Hydrometallation with Gold(III) Hydrides. Angew Chem Int Ed Engl (2016) 0.78
Luminescent Gold(III) Thiolates: Supramolecular Interactions Trigger and Control Switchable Photoemissions from Bimolecular Excited States. Chemistry (2016) 0.76
Copper and Gold Cyclic (Alkyl)(amino)carbene Complexes with Sub-Microsecond Photoemissions: Structure and Substituent Effects on Redox and Luminescent Properties. Chemistry (2017) 0.75
Synthesis, structure and cytotoxicity of cyclic (alkyl)(amino) carbene and acyclic carbene complexes of group 11 metals. Dalton Trans (2017) 0.75
Gold(III) alkyne complexes: bonding and reaction pathways. Angew Chem Int Ed Engl (2017) 0.75